CA2631917A1 - Quinolone m1 receptor positive allosteric modulators - Google Patents

Quinolone m1 receptor positive allosteric modulators Download PDF

Info

Publication number
CA2631917A1
CA2631917A1 CA002631917A CA2631917A CA2631917A1 CA 2631917 A1 CA2631917 A1 CA 2631917A1 CA 002631917 A CA002631917 A CA 002631917A CA 2631917 A CA2631917 A CA 2631917A CA 2631917 A1 CA2631917 A1 CA 2631917A1
Authority
CA
Canada
Prior art keywords
dihydroquinoline
oxo
carboxylic acid
fluoro
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002631917A
Other languages
English (en)
French (fr)
Inventor
William D. Shipe
Craig Lindsley
David Hallett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2631917A1 publication Critical patent/CA2631917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04J—MULTIPLEX COMMUNICATION
    • H04J3/00—Time-division multiplex systems
    • H04J3/02—Details
    • H04J3/06—Synchronising arrangements
    • H04J3/0635—Clock or time synchronisation in a network
    • H04J3/0638—Clock or time synchronisation among nodes; Internode synchronisation
    • H04J3/0658—Clock or time synchronisation among packet nodes
    • H04J3/0661—Clock or time synchronisation among packet nodes using timestamps
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/14—Network architectures or network communication protocols for network security for detecting or protecting against malicious traffic
    • H04L63/1441—Countermeasures against malicious traffic
    • H04L63/1458—Denial of Service
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/12—Applying verification of the received information
    • H04L63/123—Applying verification of the received information received data contents, e.g. message integrity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computer Security & Cryptography (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Computer Hardware Design (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Steroid Compounds (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
CA002631917A 2005-12-05 2006-12-04 Quinolone m1 receptor positive allosteric modulators Abandoned CA2631917A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74223405P 2005-12-05 2005-12-05
US60/742,234 2005-12-05
US78927206P 2006-04-04 2006-04-04
US60/789,272 2006-04-04
PCT/US2006/046262 WO2007067489A1 (en) 2005-12-05 2006-12-04 Quinolone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
CA2631917A1 true CA2631917A1 (en) 2007-06-14

Family

ID=37963841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002631917A Abandoned CA2631917A1 (en) 2005-12-05 2006-12-04 Quinolone m1 receptor positive allosteric modulators

Country Status (9)

Country Link
US (1) US8389545B2 (enExample)
EP (1) EP1963271B1 (enExample)
JP (1) JP5192389B2 (enExample)
AT (1) ATE475650T1 (enExample)
AU (1) AU2006322045A1 (enExample)
CA (1) CA2631917A1 (enExample)
DE (1) DE602006015851D1 (enExample)
TW (1) TW200840814A (enExample)
WO (2) WO2007067489A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530544T1 (de) 2006-06-28 2011-11-15 Merck Sharp & Dohme Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
WO2009102588A1 (en) * 2008-02-15 2009-08-20 Merck & Co., Inc. Fused pyridone m1 receptor positive allosteric modulators
CA2716921A1 (en) * 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
CA2722577A1 (en) * 2008-05-01 2009-11-05 Merck Sharp & Dohme Corp. 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
CA2733588A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. N-heterocyclic m1 receptor positive allosteric modulators
US8278453B2 (en) 2008-10-06 2012-10-02 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
WO2010047990A1 (en) 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic m1 receptor positive allosteric modulators
EP2398324B1 (en) * 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
EP2483275B1 (en) * 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8754220B2 (en) 2009-11-20 2014-06-17 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide M1 receptor positive allosteric modulators
ME02421B (me) * 2009-12-17 2016-09-20 Merck Sharp & Dohme Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida
US8507494B2 (en) 2010-04-30 2013-08-13 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived M1 receptor positive allosteric modulators
WO2011159553A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
US8940765B2 (en) 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators
US9284312B2 (en) 2011-05-17 2016-03-15 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
US9206200B2 (en) 2011-05-17 2015-12-08 Merck Sharp & Dohme Corp. N-linked lactam M1 receptor positive allosteric mogulators
AU2012328476B2 (en) 2011-10-28 2017-03-30 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2013071201A1 (en) 2011-11-11 2013-05-16 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
WO2013106795A1 (en) * 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
WO2013129622A1 (ja) 2012-03-02 2013-09-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
TR201904639T4 (tr) 2015-06-08 2019-05-21 Suven Life Sciences Ltd Muskarinik M1 reseptörü pozitif allosterik modülatörler.
EP3307741B1 (de) * 2015-06-09 2020-10-28 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
PT3347349T (pt) 2015-09-10 2019-10-30 Suven Life Sciences Ltd Derivados de fluoroindole como moduladores alostéricos positivos para recetor m1 muscarínico
WO2017155816A1 (en) * 2016-03-09 2017-09-14 Merck Sharp & Dohme Corp. Quinazoline compounds useful as m1 receptor positive allosteric modulators
US11523858B2 (en) 2017-08-11 2022-12-13 Bradley D. Vilims System and method for RF ablation with generated images of ablated tissue lesions
CN111018778B (zh) * 2019-12-30 2020-11-06 杭州师范大学 一种喹诺酮类衍生物及其制备方法和应用
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1175836A (en) * 1977-09-20 1984-10-09 Marcel Pesson Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives
JPS5845426B2 (ja) * 1978-09-29 1983-10-08 杏林製薬株式会社 置換キノリンカルボン酸誘導体
US4914110A (en) * 1984-05-11 1990-04-03 Societe De Conseils De Recherches Et D'applications Scientifiques Quinoline derivatives, their preparation and therapeutic compositions containing the same
US4623650A (en) * 1984-12-06 1986-11-18 Pfizer Inc. Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
JPS61218584A (ja) 1985-03-23 1986-09-29 Hokuriku Seiyaku Co Ltd キノリン−３−カルボン酸誘導体
JP2831000B2 (ja) * 1988-03-03 1998-12-02 大日本製薬株式会社 （２−アミノベンゾイル）酢酸エステル誘導体
FR2674247B1 (fr) 1991-03-19 1993-07-16 Bouchara Sa Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
FR2675144B1 (fr) * 1991-04-10 1995-06-16 Bouchara Sa Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
TW301607B (enExample) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
CA2250908C (en) * 1996-04-30 2012-03-13 Takeda Chemical Industries, Ltd. Combined use of gnrh agonist and antagonist
JP2000103707A (ja) * 1998-09-28 2000-04-11 Permachem Asia Ltd 工業用殺菌剤
US6583153B2 (en) * 2000-12-12 2003-06-24 Ortho-Mcneil Pharmaceutical, Inc. 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
DE10108271A1 (de) * 2001-02-21 2002-08-22 Schering Ag Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons
SE0101256D0 (sv) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of low back pain
EP1503759B1 (en) * 2002-05-14 2008-12-17 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE602005023717D1 (de) 2004-03-10 2010-11-04 Usa Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc)
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
JP2006117555A (ja) 2004-10-20 2006-05-11 Kyorin Pharmaceut Co Ltd １−トリフルオロメチル−４−キノロンカルボン酸誘導体
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
JP4853824B2 (ja) 2005-01-20 2012-01-11 アステラス製薬株式会社 キノロン誘導体を有効成分とする医薬組成物
JP4858683B2 (ja) 2005-01-20 2012-01-18 アステラス製薬株式会社 キノロン誘導体又はその塩の製造法

Also Published As

Publication number Publication date
JP5192389B2 (ja) 2013-05-08
WO2007100366A2 (en) 2007-09-07
TW200840814A (en) 2008-10-16
US20100317692A1 (en) 2010-12-16
US8389545B2 (en) 2013-03-05
EP1963271B1 (en) 2010-07-28
EP1963271A1 (en) 2008-09-03
WO2007067489A1 (en) 2007-06-14
ATE475650T1 (de) 2010-08-15
JP2009518309A (ja) 2009-05-07
DE602006015851D1 (de) 2010-09-09
AU2006322045A1 (en) 2007-06-14
WO2007100366A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
EP1963271B1 (en) Quinolone m1 receptor positive allosteric modulators
EP2037739B1 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
EP2483275B1 (en) HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
EP2312949B1 (en) N-heterocyclic m1 receptor positive allosteric modulators
EP2252151B1 (en) Quinolizidinone m1 receptor positive allosteric modulators
US20110201607A1 (en) Fused heterocyclic m1 receptor positive allosteric modulators
EP2212322B1 (en) Quinolizidinone m1 receptor positive allosteric modulators
EP2252299B1 (en) Fused pyridone m1 receptor positive allosteric modulators
EP2268280B1 (en) Quinolizidinone M1 receptor positive allosteric modulators
US8293914B2 (en) 4-OXO,1-4-dihydroquinoline M1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
FZDE Discontinued